ReviewCurrent drug targets2026
Novel Approaches to Diagnosing and Treating Non-alcoholic Fatty Liver Disease: Opportunities and Accomplishments.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of nonalcoholic fatty liver disease (NAFLD) provides a more precise understanding of the origins of the disease. This is crucial for identifying risk factors, monitoring patients, and developing novel pharmacological approaches for treating MAFLD. Single-nucleotide variations in genes related to fat and carbohydrate metabolism, as well as the state of gut microbiota, are becoming increasingly important. Currently, MAFLD management primarily relies on significant lifestyle modifications, including avoiding alcohol and smoking, and adopting a Mediterranean-style diet. For individuals with excess weight, bariatric surgery remains the only effective option. Among approved medications for MAFLD, only vitamin E and pioglitazone are currently available. However, the potential for fluid retention with pioglitazone limits its use. Therefore, it is important to explore existing treatments and identify new physiological pathways in MAFLD to develop innovative therapies that can effectively address this condition.
Indexed as
Identifiers
42227513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.